Post

New research · Ophthalmology
Clinical ophthalmology (Auckland, N.Z.) · 5d
Cohort studyClinical ophthalmology (Auckland, N.Z.) · 2026

Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.

Louise A Mawn, Erin Moore Shriver, Madhura Tamhankar … Haridarshan Patel
Read paper
OphthalmologyCohort study

Most patients with thyroid eye disease completed the full teprotumumab treatment course.

Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.

Louise A Mawn … Haridarshan Patel
Clinical ophthalmology (Auckland, N.Z.) · 2026
Purpose

To describe patient characteristics and teprotumumab treatment patterns among patients with thyroid eye disease (thyroid eye disease), using large-scale, linked clinical and claims data.

Methods

This was an observational, retrospective cohort study using linked data from the American Academy of Ophthalmology IRIS ® Registry (Intelligent Research in Sight) and Komodo Health Research Dataset (KRD; 2019-2024).

n = 2,886 patients
65%
Results
65%
patients with thyroid eye disease completed the full treatment course
n = 2,886 patients
More results

At baseline, 79% had ≥1 eye sign or symptom (proptosis: 45%; diplopia: 29%).

Among 356 patients with CAS recorded, 91% had active disease (CAS ≥3/7 or 4/10).

Teprotumumab was initiated within 12 months of thyroid eye disease diagnosis in 70% of patients.

More results

Retreatment with teprotumumab occurred in 10% of patients completing the first course, 26% of whom completed the second course.

“
Conclusion · 1 of 2

This large real-world analysis reveals high baseline thyroid eye disease burden, teprotumumab adoption within one year of diagnosis, and adherence to FDA-indicated dosing.

Conclusion · 2 of 2

The findings reflect evolving clinical practice in thyroid eye disease management and support the need for ongoing research to assess how teprotumumab may influence the natural history of disease over time.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment